CSIMarket Company Name, Ticker, Competitors, else..
 
Icosavax Inc   (NASDAQ: ICVX)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 50
 Employees 31
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -97
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 5

Business Description


Icosavax Inc is a biotechnology company that focuses on the development of vaccines for infectious diseases. The company uses a proprietary virus-like particle (VLP) technology to create safe and effective vaccines. Their vaccines are designed to mimic the structure and characteristics of the target virus to stimulate a robust immune response. Icosavax Inc aims to address global health challenges by developing vaccines for diseases such as respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), which currently have limited treatment options. The company has a strong emphasis on research and development and collaborates with academic institutions and industry partners to advance their vaccine candidates.


   Company Address: 1930 Boren Avenue Seattle 98101 WA
   Company Phone Number: 737-0085   Stock Exchange / Ticker: NASDAQ ICVX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALEC   -2.59%    
MRNA        11.17% 
NVAX        0.48% 
SABS   -5.31%    
STRO   -6.79%    
TSBX        1.08% 
• View Complete Report
   



Merger and Acquisition

AstraZeneca Strengthens Late-Stage Vaccine Pipeline with Acquisition of Icosavax: Paving the Way for Breakthrough RSV and hMPV Combination Vaccine

Published Tue, Dec 12 2023 12:00 PM UTC



In a significant move to bolster its position in the biopharmaceutical arena, AstraZeneca has recently announced its definitive agreement to acquire Icosavax, Inc. The Delaware-based clinical-stage biopharmaceutical company has gained recognition for its cutting-edge protein virus-like particle (VLP) platform, which has shown great promise in the development of dif...
Clinical Study

Big Step Forward in Respiratory Virus Prevention: Icosavax’s Landmark Phase 2 Vaccine Results Promising for Older Adults' Protection.

Published Tue, Dec 12 2023 7:00 AM UTC


In the pursuit of the ultimate way to combat RSV and hMPV, the combination VLP vaccine, IVX-A12, is a blend of two vaccines previously being developed separately the IVX-RSV and the IVX-hMPV. The combination of these two has shown promising results in interim Phase 2, thereby justifying the move towards a combined vaccine.
Phase 2 trials, which involve hundreds o...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 17.59
Working Capital Ratio 18.06
Leverage Ratio (MRQ) 0.08
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.22 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 4.58 $
Book Value 4.64 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -3,119,742
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.